Abstract

Introduction: The diagnosis of infections in allogeneic stem-cell transplant (allo-SCT) patients is challenging. There is a need for improved diagnostics that can quickly and accurately detect a broad range of viruses, bacteria, and fungi that can infect these patients to guide targeted therapy.

Methods: We enrolled 20 patients in a prospective study evaluating the Karius plasma next-generation sequencing (plasma NGS) test to detect infections in allo-SCT patients. Nine patients received myeloablative conditioning and 11 underwent reduced intensity conditioning. All patients were free of known active infections at the initiation of the transplant conditioning regimen. Patients had baseline plasma samples drawn prior to transplant followed by weekly collections during engraftment and at onset of febrile episodes. Samples were transferred to the Karius CLIA/CAP laboratory (Redwood City, CA) where cell-free DNA was extracted from plasma and NGS performed. Human sequences were computationally removed and remaining reads were aligned against a curated pathogen database. Genomic evidence of organisms present at a significance level above a predefined threshold were reported.

Results: Cytomegalovirus (CMV) DNA was identified in 12/20 patients overall, and 12/16 CMV IgG seropositive patients. Using a nearest-neighbor method, 61 pairs of observations were identified for a comparison of plasma NGS and CMV qPCR collected within one day of each other. Positive agreement (PPA) between plasma NGS and CMV qPCR was 84.1% (37/44). PPA was 100% (20/20) when values below the lower limit of quantitation (<137 IU/ml) for CMV qPCR were excluded. In addition to CMV, plasma NGS detected EBV (5/20 patients), HHV-6B (4/20 patients), BK virus (4/20 patients) and Torque teno viruses (4/20 patients), with 9 subjects experiencing co-infections. Nine subjects had co-infections with two or more viruses. Plasma NGS also detected pathogens prior to conventional tests being ordered in two patients with subsequently confirmed acute infections; Staphylococcus aureus was detected one day prior to blood culture in one patient and Chlamydia trachomatis 30 days prior to targeted testing in a second patient. These two cases highlight the potential of plasma NGS to detect pathogens in SCT patients early when used as a monitoring tool.

Conclusions: Karius has developed a novel NGS plasma test that can simultaneously identify pathogens in allo-SCT patients. The test had 100% concordance with CMV qPCR above the lower level of quantitation. Further work is ongoing to determine the lower limits of detection for the plasma NGS test. Using NGS to monitor SCT patients for infection could permit earlier detection of pathogens, enabling earlier targeted therapy for selected pathogens and preemption of clinical infection sequalae in this vulnerable population.

Disclosures

Seng: Karius, Inc.: Employment. Hollemon: Karius, Inc.: Employment. Hong: Karius, Inc.: Employment. Blauwkamp: Karius, Inc.: Employment, Membership on an entity's Board of Directors or advisory committees. Kertesz: Karius, Inc.: Employment, Membership on an entity's Board of Directors or advisory committees. Wong: Karius, Inc.: Research Funding. Logan: Kite: Research Funding; Astellas: Research Funding; Novartis: Consultancy, Research Funding; Shire: Consultancy; Pharmacyclics: Research Funding; Incyte: Consultancy; Amgen: Consultancy; Jazz: Consultancy. Chin-Hong: Karius, Inc.: Research Funding.

Author notes

*

Asterisk with author names denotes non-ASH members.